Acosta ST, Riverón FG, Marín PLC, Castillo CY, Martínez RL

Language: Spanish
References: 20
Page: 595-606
PDF size: 1044.64 Kb.

ABSTRACT

Introduction: Mucopolysaccharidosis are caused by the deficiency in lysosomal enzyme activities necessary to degrade the glycosaminoglycans. These syndromes share many clinical characteristics although in variable degrees. Clinical manifestations imply multiple organs systems and some have enzyme replacement treatment. Many investigations deal on the presence of oxidative stress in those who suffer it, but this condition has not still been studied in Cuban patients.
Objective: To evaluate parameters of oxidative stress in Cuban patients with mucopolysaccharidosis.
Methods: A cases and controls study which included 7 children with mucopolysaccharidosis types I, II, III and IV (cases) and 21 apparently healthy children, paired by age and sex (control group) was carried out. The plasmatic levels of malondialdehide, advanced products of proteins oxidation, free thiol groups and blood chemistry markers were measured. The intraerythrocytic activities of superoxide dismutase, catalase and that of glutathione peroxidase were quantified. All the used techniques were spectrophotometrical.
Results: The patients showed an increase, both in the calcium levels as in the oxidation of proteins and lipids, in comparison with the control group and the Cuban values reference. There was a decrease in the activity of the enzyme superoxide dismutase and the concentrations of thiols groups. There were no differences for the rest of the measured parameters.
Conclusions: The increase of the oxidative damage and the decrease of the anti-oxidant capacity suggest the presence of oxidative stress in those Cuban patients.

REFERENCES

1. US National Library of Medicine. Genetics Home Reference provides consumer-friendly information about the effects of genetic variation on human health [citado 26/11/2017]. Disponible en: https://ghr.nlm.nih.gov/

2. Baldellou Vázquez A, Sanjurjo Crespo P, Del Toro Riera M. Enfermedades Lisosomales. En: Sanjurjo P y Baldellou A, Editores. Diagnóstico y tratamiento de las enfermedades metabólicas hereditarias. 4 ed. Madrid: Ergón; 2014. p. 861-95.

3. Pomin VH, Mulloy B. Glycosaminoglycans and proteoglycans. Pharmaceuticals. 2018; 11(1):27.

4. Annunziata I, Sano R, d’Azzo A. Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. Cell Death Dis. 2018;9(3):328.

5. Saffari A, Kölker S, Hoffmann GF, Ebrahimi-Fakhari D. Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases. J Inherit Metab Dis. 2017;40(5):631-40.

6. Pérez C, Riverón G, Fernández IM, del Castillo NP, Martínez O, Gutiérrez R et al. Marcadores de estrés oxidativo y genotoxicidad en trabajadores cubanos con exposición ocupacional prolongada al plomo. Rev Cubana Salud y Trabajo. 2015;16(3):20-5.

7. Reolon GK, Reinke A, de Oliveira MR, Braga LM, Camassola M, Andrades ME, et al. Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cell Mol Neurobiol. 2009;29(4):443-48.

8. Negretto GW, Deon M, Biancini GB, Burin MG, Giugliani R, Vargas CR. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Cell Biol Toxicol. 2014;30(4):189-93.

9. Trudel S, Trécherel E, Gomila C, Peltier M, Aubignat M, Gubler B, Morlière P, et al. Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B. J Neurosci Res. 2015;93(3):424-32.

10. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev. 2000;32(3-4):307-26.

11. Donida B, Marchetti DP, Biancini GB, Deon M, Manini PR, da Rosa HT, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2015;1852(5):1012-9.

12. Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Thérond P, Scherman D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab. 2011;103(1):18-25.

13. Silva de Mello A, Rocha Frusciante M, Gonçalves Kneib L, Bortolato G, Cé J, et al. Α-glucosidase deficiency promotes increasing protein oxidative damage in Pompe disease patients. J Alzheimers Dis Parkinsonism. 2017;7(1):306-10.

14. Ighodaro OM, Akinloye OA. First Line Defence Antioxidants-Superoxide Dismutase, Catalase and Glutathione Peroxidase: their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54(4):287-93.

15. Comini MA. Measurement and meaning of cellular thiol: disulfide redox status. Free Radic Res. 2016;50(2):246-71.

16. McBean GJ, Aslan M, Griffiths HR, Torrão RC. Thiol redox homeostasis in neurodegenerative disease. Redox Biol. 2015;5:186-94.

17. Denzoin LA, Soraci AL, Tapia MO. Homeostasis del glutatión. Acta Bioquím Clin Latinoam. 2013;47(3):529-39.

18. Comini MA. Measurement and meaning of cellular thiol: disulfide redox status. Free Radic Res. 2016;50(2):246-71.

19. Medina D, Ballabio A. Lysosomal calcium regulates autophagy. Autophagy. 2015;11(6):970-2.

20. Viana GM, do Nascimento CC, Paredes Gamero EJ, D'Almeida V. Altered cellular homeostasis in murine MPS I fibroblasts: evidence of cell-specific physiopathology. JIMD Rep. 2017;36:109-16.